Mycoplasma pneumoniae detections before and during the COVID-19 pandemic : results of a global survey, 2017 to 2021
BackgroundMycoplasma pneumoniae respiratory infections are transmitted by aerosol and droplets in close contact.AimWe investigated global M. pneumoniae incidence after implementation of non-pharmaceutical interventions (NPIs) against COVID-19 in March 2020.MethodsWe surveyed M. pneumoniae detections from laboratories and surveillance systems (national or regional) across the world from 1 April 2020 to 31 March 2021 and compared them with cases from corresponding months between 2017 and 2020. Macrolide-resistant M. pneumoniae (MRMp) data were collected from 1 April 2017 to 31 March 2021.ResultsThirty-seven sites from 21 countries in Europe, Asia, America and Oceania submitted valid datasets (631,104 tests). Among the 30,617 M. pneumoniae detections, 62.39% were based on direct test methods (predominantly PCR), 34.24% on a combination of PCR and serology (no distinction between methods) and 3.37% on serology alone (only IgM considered). In all countries, M. pneumoniae incidence by direct test methods declined significantly after implementation of NPIs with a mean of 1.69% (SD ± 3.30) compared with 8.61% (SD ± 10.62) in previous years (p < 0.01). Detection rates decreased with direct but not with indirect test methods (serology) (-93.51% vs + 18.08%; p < 0.01). Direct detections remained low worldwide throughout April 2020 to March 2021 despite widely differing lockdown or school closure periods. Seven sites (Europe, Asia and America) reported MRMp detections in one of 22 investigated cases in April 2020 to March 2021 and 176 of 762 (23.10%) in previous years (p = 0.04).ConclusionsThis comprehensive collection of M. pneumoniae detections worldwide shows correlation between COVID-19 NPIs and significantly reduced detection numbers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 27(2022), 19 vom: 26. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meyer Sauteur, Patrick M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.05.2022 Date Revised 15.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2022.27.19.2100746 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340798408 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340798408 | ||
| 003 | DE-627 | ||
| 005 | 20231226010302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2022.27.19.2100746 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340798408 | ||
| 035 | |a (NLM)35551702 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meyer Sauteur, Patrick M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mycoplasma pneumoniae detections before and during the COVID-19 pandemic |b results of a global survey, 2017 to 2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2022 | ||
| 500 | |a Date Revised 15.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BackgroundMycoplasma pneumoniae respiratory infections are transmitted by aerosol and droplets in close contact.AimWe investigated global M. pneumoniae incidence after implementation of non-pharmaceutical interventions (NPIs) against COVID-19 in March 2020.MethodsWe surveyed M. pneumoniae detections from laboratories and surveillance systems (national or regional) across the world from 1 April 2020 to 31 March 2021 and compared them with cases from corresponding months between 2017 and 2020. Macrolide-resistant M. pneumoniae (MRMp) data were collected from 1 April 2017 to 31 March 2021.ResultsThirty-seven sites from 21 countries in Europe, Asia, America and Oceania submitted valid datasets (631,104 tests). Among the 30,617 M. pneumoniae detections, 62.39% were based on direct test methods (predominantly PCR), 34.24% on a combination of PCR and serology (no distinction between methods) and 3.37% on serology alone (only IgM considered). In all countries, M. pneumoniae incidence by direct test methods declined significantly after implementation of NPIs with a mean of 1.69% (SD ± 3.30) compared with 8.61% (SD ± 10.62) in previous years (p < 0.01). Detection rates decreased with direct but not with indirect test methods (serology) (-93.51% vs + 18.08%; p < 0.01). Direct detections remained low worldwide throughout April 2020 to March 2021 despite widely differing lockdown or school closure periods. Seven sites (Europe, Asia and America) reported MRMp detections in one of 22 investigated cases in April 2020 to March 2021 and 176 of 762 (23.10%) in previous years (p = 0.04).ConclusionsThis comprehensive collection of M. pneumoniae detections worldwide shows correlation between COVID-19 NPIs and significantly reduced detection numbers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Face masks | |
| 650 | 4 | |a Mycoplasma pneumoniae | |
| 650 | 4 | |a nonpharmaceutical interventions (NPIs) | |
| 650 | 4 | |a personal protective equipment (PPE) | |
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 7 | |a Macrolides |2 NLM | |
| 700 | 1 | |a Beeton, Michael L |e verfasserin |4 aut | |
| 700 | 1 | |a Uldum, Søren A |e verfasserin |4 aut | |
| 700 | 1 | |a Bossuyt, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeulen, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Loens, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Pereyre, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Bébéar, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Keše, Darja |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Afshar, Baharak |e verfasserin |4 aut | |
| 700 | 1 | |a Chalker, Victoria J |e verfasserin |4 aut | |
| 700 | 1 | |a Greub, Gilbert |e verfasserin |4 aut | |
| 700 | 1 | |a Nir-Paz, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Dumke, Roger |e verfasserin |4 aut | |
| 700 | 0 | |a ESGMAC–MyCOVID Study Team |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Noémie |e investigator |4 oth | |
| 700 | 1 | |a Andreutti, Corinne |e investigator |4 oth | |
| 700 | 1 | |a Agyeman, Philipp K A |e investigator |4 oth | |
| 700 | 1 | |a Aebi, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Buettcher, Michael |e investigator |4 oth | |
| 700 | 1 | |a Kottanattu, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Gaia, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Imkamp, Frank |e investigator |4 oth | |
| 700 | 1 | |a Zbinden, Reinhard |e investigator |4 oth | |
| 700 | 1 | |a Berger, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Niederer-Loher, Anita |e investigator |4 oth | |
| 700 | 1 | |a Barbey, Florence |e investigator |4 oth | |
| 700 | 1 | |a Egli, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Schmid, Hanna |e investigator |4 oth | |
| 700 | 1 | |a Heininger, Ulrich |e investigator |4 oth | |
| 700 | 1 | |a Papan, Cihan |e investigator |4 oth | |
| 700 | 1 | |a Kohns Vasconcelos, Malte |e investigator |4 oth | |
| 700 | 1 | |a Henrich, Birgit |e investigator |4 oth | |
| 700 | 1 | |a Mackenzie, Colin |e investigator |4 oth | |
| 700 | 1 | |a Schneider, Gerlinde |e investigator |4 oth | |
| 700 | 1 | |a van Westreenen, Mireille |e investigator |4 oth | |
| 700 | 1 | |a Verkaik, Nelianne J |e investigator |4 oth | |
| 700 | 1 | |a van Rossum, Annemarie M C |e investigator |4 oth | |
| 700 | 1 | |a Emborg, Hanne-Dorthe |e investigator |4 oth | |
| 700 | 1 | |a Peltola, Ville |e investigator |4 oth | |
| 700 | 1 | |a Renko, Marjo |e investigator |4 oth | |
| 700 | 1 | |a Tapiainen, Terhi |e investigator |4 oth | |
| 700 | 1 | |a Heinonen, Santtu |e investigator |4 oth | |
| 700 | 1 | |a Døllner, Henrik |e investigator |4 oth | |
| 700 | 1 | |a Rodrigues, Fernanda |e investigator |4 oth | |
| 700 | 1 | |a Matsas, Minos |e investigator |4 oth | |
| 700 | 1 | |a Kalogera, Eleni |e investigator |4 oth | |
| 700 | 1 | |a Petridou, Evangelia |e investigator |4 oth | |
| 700 | 1 | |a Kopsidas, Ioannis |e investigator |4 oth | |
| 700 | 1 | |a Zaoutis, Theoklis E |e investigator |4 oth | |
| 700 | 1 | |a Michael-Gayego, Ayelet |e investigator |4 oth | |
| 700 | 1 | |a Ouchi, Kazunobu |e investigator |4 oth | |
| 700 | 1 | |a Namkoong, Ho |e investigator |4 oth | |
| 700 | 1 | |a Hsieh, Yu-Chia |e investigator |4 oth | |
| 700 | 1 | |a Maiwald, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Loo, Liat Hui |e investigator |4 oth | |
| 700 | 1 | |a Chaudhry, Rama |e investigator |4 oth | |
| 700 | 1 | |a Kociolek, Larry K |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez, Nadia |e investigator |4 oth | |
| 700 | 1 | |a Lorenz, David |e investigator |4 oth | |
| 700 | 1 | |a De Almeida, Mary |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 27(2022), 19 vom: 26. Mai |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:19 |g day:26 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2022.27.19.2100746 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 19 |b 26 |c 05 | ||